Respicardia Announces Enrollment Of First Patients In Pivotal Trial Of The remede® System For The Treatment Of Central Sleep Apnea

03:13 EDT 19 Aug 2013 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
MINNEAPOLIS, Aug. 19, 2013 /PRNewswire/ -- Respicardia®, a developer of implantable therapies to improve respiratory and cardiovascular health, announced that the first patients have been enrolled in the pivotal trial to evaluate the reme...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Respicardia Announces Enrollment Of First Patients In Pivotal Trial Of The remede® System For The Treatment Of Central Sleep Apnea"

Search BioPortfolio:
Advertisement

Relevant Topic

Cardiovascular disease (CVD)
Latest News Clinical Trials Research Drugs Reports Corporate
Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina and heart attack), heart failure, congenital heart disease and stroke. It is also known as heart and circulatory disease. Coron...

Advertisement

Searches Linking to this Story